NASDAQ:OABI OmniAb (OABI) Stock Price, News & Analysis $2.42 -0.05 (-2.02%) Closing price 04:00 PM EasternExtended Trading$2.41 -0.01 (-0.41%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About OmniAb Stock (NASDAQ:OABI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OmniAb alerts:Sign Up Key Stats Today's Range$2.41▼$2.4750-Day Range$2.27▼$3.8852-Week Range$2.23▼$5.54Volume889,259 shsAverage Volume551,071 shsMarket Capitalization$341.74 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewOmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.Read More… Remove Ads OmniAb Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreOABI MarketRank™: OmniAb scored higher than 60% of companies evaluated by MarketBeat, and ranked 425th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOmniAb has only been the subject of 3 research reports in the past 90 days.Read more about OmniAb's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OmniAb are expected to grow in the coming year, from ($0.61) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OmniAb is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OmniAb is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmniAb has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about OmniAb's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.65% of the float of OmniAb has been sold short.Short Interest Ratio / Days to CoverOmniAb has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in OmniAb has recently decreased by 6.03%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOmniAb does not currently pay a dividend.Dividend GrowthOmniAb does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.65% of the float of OmniAb has been sold short.Short Interest Ratio / Days to CoverOmniAb has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in OmniAb has recently decreased by 6.03%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News Sentiment0.57 News SentimentOmniAb has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for OmniAb this week, compared to 2 articles on an average week. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, OmniAb insiders have sold 27.44% more of their company's stock than they have bought. Specifically, they have bought $295,512.00 in company stock and sold $376,601.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of OmniAb is held by insiders.Percentage Held by Institutions72.08% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OmniAb's insider trading history. Receive OABI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter. Email Address OABI Stock News HeadlinesOmniAb, Inc. (NASDAQ:OABI) Director John L. Higgins Acquires 125,750 SharesMarch 21, 2025 | insidertrades.comOmniAb price target lowered to $4 from $7 at RBC CapitalMarch 27 at 11:26 PM | markets.businessinsider.comNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. March 28, 2025 | Paradigm Press (Ad)Q1 Earnings Forecast for OmniAb Issued By HC WainwrightMarch 25 at 1:13 AM | americanbankingnews.comQ4 Earnings Forecast for OmniAb Issued By HC WainwrightMarch 23, 2025 | americanbankingnews.comLeerink Partnrs Brokers Reduce Earnings Estimates for OmniAbMarch 23, 2025 | americanbankingnews.comOmniAb price target lowered to $4 from $8 at TD CowenMarch 21, 2025 | msn.comOmniAb price target lowered to $6 from $8 at BenchmarkMarch 21, 2025 | markets.businessinsider.comSee More Headlines OABI Stock Analysis - Frequently Asked Questions How have OABI shares performed this year? OmniAb's stock was trading at $3.54 on January 1st, 2025. Since then, OABI stock has decreased by 31.6% and is now trading at $2.42. View the best growth stocks for 2025 here. How were OmniAb's earnings last quarter? OmniAb, Inc. (NASDAQ:OABI) issued its quarterly earnings results on Tuesday, March, 18th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. The company had revenue of $10.80 million for the quarter, compared to analysts' expectations of $10.13 million. OmniAb had a negative trailing twelve-month return on equity of 20.97% and a negative net margin of 308.78%. Who are OmniAb's major shareholders? OmniAb's top institutional investors include Janus Henderson Group PLC (5.64%), Vanguard Group Inc. (3.58%), Dimensional Fund Advisors LP (2.14%) and Chicago Capital LLC (2.11%). Insiders that own company stock include Charles S Berkman, Kurt A Gustafson and Jennifer R Cochran. View institutional ownership trends. How do I buy shares of OmniAb? Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OmniAb own? Based on aggregate information from My MarketBeat watchlists, some other companies that OmniAb investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Adobe (ADBE). Company Calendar Last Earnings3/18/2025Today3/28/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:OABI CIK1846253 Webwww.omniab.com Phone510-250-7800FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$11.00 Low Stock Price Target$4.00 Potential Upside/Downside+189.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,620,000.00 Net Margins-308.78% Pretax Margin-373.44% Return on Equity-20.97% Return on Assets-18.05% Debt Debt-to-Equity RatioN/A Current Ratio4.62 Quick Ratio4.62 Sales & Book Value Annual Sales$26.39 million Price / Sales12.92 Cash FlowN/A Price / Cash FlowN/A Book Value$2.69 per share Price / Book0.90Miscellaneous Outstanding Shares141,216,000Free Float129,071,000Market Cap$341.04 million OptionableOptionable Beta-0.14 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:OABI) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredRevealed: The Chip Stock Redefining AI as We Know ItIn this urgent presentation, Wall Street's so-called "AI Oracle" unveils the name of a small American tech fir...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OmniAb, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OmniAb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.